New Treatment for Nocturnal Enuresis in Children

Last updated: July 11, 2024
Sponsor: Sohag University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Enuresis

Urinary Incontinence

Nocturia

Treatment

Sulbutiamine

Imipramine

Clinical Study ID

NCT06497647
Soh-Med-24-06-05MS
  • Ages 6-18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age : 6 - 18 years old.

  • All children diagnosed by Primary monosymptomatic nocturnal enuresis in this agegroup.

Exclusion

Exclusion Criteria:

  • Secondary nocturnal enuresis (child who has been continent for at least 6 monthsbefore the onset of bedwetting ).

  • congenital anomalies (Posterior urethral valve , ectopic ureter , ectopia vesica ,...)

  • history of previous lower urinary tract surgery (Multiple hypospadias surgeries ,..., )

  • neurogenic bladder (as underactive bladder ).and urge incontinence.

  • presence of post-void residual urine greater than 20% of functional bladdercapacity.

  • history or evidence of disorders in other organs such as (cardiovascular systemdisease), liver , psychological problems , evident allergic reaction to bothmedication.

Study Design

Total Participants: 450
Treatment Group(s): 2
Primary Treatment: Sulbutiamine
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
November 30, 2024

Connect with a study center

  • Sohag Faculty of Medecine

    Sohag,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.